Pricing Log in Create free account
Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Charles River Laboratories International, Inc. 10-K filed Feb 18, 2026

Fiscal year 2025 · Period ended Dec 27, 2025 · Filed · accepted 9:21 AM ET · Document on sec.gov · Filing index

Red flags

  • Impairment

    Charles River Laboratories International, Inc. recorded a goodwill impairment of $165.0 million in fiscal 2025

    10-K filed · The filing · sec.gov

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 7, Management’s Discussion and Analysis, against the 10-K filed Feb 19, 2025: 21 added · 15 removed · 47 modified; 14 with only figures updated; 11 moved without change

83 more changes in this Item, word by word, in Powerpack.

Powerpack